Gal-dMor-Gem
Gal-dMor-Gem is a selective senescent cell scavenger, Apoptosis inducer, and a prodrug of Gemcitabine (HY-17026). Gal-dMor-Gem releases Gemcitabine upon activation by Esterases and β-gal. Gal-dMor-Gem reduces SA-β-gal, preferentially induces apoptosis in senescent cells, regulates apoptosis-related proteins, accumulates in senescent tissues, and ameliorates senescence-related organ phenotypes. Gal-dMor-Gem is applicable to research on chemotherapy-induced senescence.
For research use only. We do not sell to patients.
- CAS No.: 3051812-84-8
- Formula: C41H53F2N5O18
- Molecular Weight:941.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Gal-dMor-Gem (0.1-100 μM; 48 h) potently and selectively reduces the viability of senescent A549/Dox and A549/H2O2 cells, with better efficacy than that on non-senescent A549 cells; its senolytic indices are 48.3 and 56.7, with IC50 values of 1.58 μM and 1.40 μM, respectively[1].
Gal-dMor-Gem (esterase 100 U/mL, β-galactosidase 5 U/mL) releases active gemcitabine (Gem) at a faster rate than Gal-Gem and Gal-Mor-Gem upon activation by esterase and β-gal, with a release rate of 79.9% after 3 h and a cumulative release rate of 92.4% after 12 h[1].
Gal-dMor-Gem (3-48 h) eliminates senescent A549/Dox cells faster and more effectively than Gal-Gem, reducing cell viability to 20.9% after 36 h of treatment[1].
Gal-dMor-Gem (100 μM; 36 h) selectively induces apoptosis in senescent A549/Dox cells, but shows no such selectivity toward non-senescent A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:nonsenescent A549 cells, senescent A549/Dox cells, senescent A549/H2O2 cells
-
Concentration:0.1-100 μM
-
Incubation Time:48 h
-
Result:Showed selective cytotoxicity toward senescent cells over nonsenescent cells.
Reduced cell viability to 91.7% for A549, 83.0% for A549/Dox, and 80.6% for A549/H2O2 at 0.1 μM.
Reduced cell viability to 57.1% for A549, 17.8% for A549/Dox, and 11.3% for A549/H2O2 at 100 μM.
Achieved IC50 values of 79.54 μM for A549, 1.58 μM for A549/Dox, and 1.40 μM for A549/H2O2.
Resulted in senolytic indices of 48.3 (A549/Dox) and 56.7 (A549/H2O2).
-
Cell Line:nonsenescent A549 cells, senescent A549/Dox cells
-
Concentration:100 μM
-
Incubation Time:36 h
-
Result:Induced apoptosis in 10.1% of nonsenescent A549 cells and 50.4% of senescent A549/Dox cells.
Induced lower apoptosis in nonsenescent A549 cells and higher apoptosis in senescent A549/Dox cells compared to Gal-Gem, which induced apoptosis in 21.5% of nonsenescent A549 cells and 32.0% of senescent A549/Dox cells.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | T1/2 | MRT0-t | AUC0-t | AUC0-∞ |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 1.0 mg/kg | i.p. | 254 ng/mL | 3.47 h | 8.49 h | 6.50 h | 752 ng·h/mL | 775 ng·h/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (Dox-induced systemic senescence model)[1]
-
Dosage:0.2 mg/kg; 0.5 mg/kg; 1.0 mg/kg
-
Administration:i.p.; once weekly; 3 doses
-
Result:Increased body weight in treated senescent mice relative to untreated controls; achieved 14.6% body weight increase at 0.5 mg/kg and 17.8% body weight increase at 1.0 mg/kg relative to day 10.
Improved liver (ALT, AST) and kidney (CREA, UREA) function markers across all doses, with greater restorative effects than the reference compound at 0.5 mg/kg.
Reduced lung SA-β-gal-positive cells from 62.4% to 44.2% at 0.2 mg/kg, to 16.9% at 0.5 mg/kg, and to 9.9% at 1.0 mg/kg (approaching healthy levels of 6.0%).
Increased lung LMNB1-positive nuclei from 43.9% to 57.6% at 0.2 mg/kg, to 74.9% at 0.5 mg/kg, and to 82.0% at 1.0 mg/kg (approaching healthy levels of 86.0%).
Reduced lung relative IL-6 fluorescence intensity from 1450.5 to 1205.0 at 0.2 mg/kg, to 678.1 at 0.5 mg/kg, and to 450.0 at 1.0 mg/kg.
Reduced liver SA-β-gal-positive cells from 88.1% to 63.7% at 0.2 mg/kg, to 21.7% at 0.5 mg/kg, and to 13.2% at 1.0 mg/kg (approaching healthy levels of 6.9%).
Reduced liver relative p21 expression from 0.93 to 0.78 at 0.2 mg/kg, to 0.58 at 0.5 mg/kg, and to 0.50 at 1.0 mg/kg.
Reduced liver relative p53 expression to 0.49 at 0.5 mg/kg and to 0.43 at 1.0 mg/kg (approaching healthy levels of 0.38).
Reduced SA-β-gal-positive cells, increased LMNB1-positive nuclei, and reduced IL-6 levels in heart and kidney across all doses, with greater effects than the reference compound at 0.5 mg/kg; restored these markers to near healthy levels at 1.0 mg/kg.
Chemical Information
-
CAS No. 3051812-84-8
-
Molecular Weight 941.88
-
Formula C41H53F2N5O18
-
SMILES
O=C(OCC1=CC(CN2CCOCC2)=C(O[C@H]3[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O3)C(CN4CCOCC4)=C1)NC5=NC(N(C=C5)[C@@H]6O[C@@H]([C@H](C6(F)F)O)CO)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)